Cargando…

Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration—A Narrative Review

SIMPLE SUMMARY: In this article, we outline updates on the clinical development of savolitinib, a novel, reversible c-MET kinase inhibitor conditionally approved in China for treatment of advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping mutation (METex14). Savoliti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Xiaokuan, Lu, Yao, Lu, Shun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776447/ https://www.ncbi.nlm.nih.gov/pubmed/36551608 http://dx.doi.org/10.3390/cancers14246122

Ejemplares similares

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON
por: Hartmaier, Ryan J., et al.
Publicado: (2023)

Case Report: A Lung Adenocarcinoma With Brain Metastasis Harbored Novel MET 14 Skipping Alteration Sensitive to Savolitinib
por: Li, Jian, et al.
Publicado: (2022)

Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
por: Lu, Shun, et al.
Publicado: (2022)

Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model
por: Jones, Rhys D.O., et al.
Publicado: (2023)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Circulating tumour DNA biomarkers in savolitinib-treated patients with non-small cell lung cancer harbouring MET exon 14 skipping alterations: a post hoc analysis of a pivotal phase 2 study
por: Yu, Yongfeng, et al.
Publicado: (2022)

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer
por: Piper-Vallillo, Andrew J., et al.
Publicado: (2020)

Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation
por: Henry, Ryan E., et al.
Publicado: (2016)

Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
por: Han, Sen, et al.
Publicado: (2019)

Dramatic response and acquired resistance to savolitinib in advanced intrahepatic cholangiocarcinoma with MET amplification: a case report and literature review
por: Zhou, Kexun, et al.
Publicado: (2023)

Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review
por: Tian, Jiangfang, et al.
Publicado: (2022)

Savolitinib: A Promising Targeting Agent for Cancer
por: Lee, Tae Seung, et al.
Publicado: (2023)

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers
por: Wang, Yakun, et al.
Publicado: (2022)

Case Report: Prompt Response to Savolitinib in a Case of Advanced Gastric Cancer With Bone Marrow Invasion and MET Abnormalities
por: Ye, Wen, et al.
Publicado: (2022)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report
por: Fu, Meng, et al.
Publicado: (2022)

Case report: Savolitinib induced severe adverse reactions resembling septic shock in an HIV-1–positive patient with advanced non-small cell lung cancer
por: Xiong, Ye, et al.
Publicado: (2023)

Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial
por: Choueiri, Toni K., et al.
Publicado: (2020)

Significant role of savolitinib in a case of advanced gastric cancer with abnormal mesenchymal‐epithelial transition factor (MET): A case report
por: He, XinCheng, et al.
Publicado: (2022)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
por: Le, Xiuning, et al.
Publicado: (2021)

Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene
por: Fischer, Alessa, et al.
Publicado: (2022)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
por: Hong, Lingzhi, et al.
Publicado: (2021)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

SAMETA: A Phase III study of savolitinib + durvalumab vs sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma
por: Chouieri, Toni
Publicado: (2023)

The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review
por: Liu, Yu, et al.
Publicado: (2021)

The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review
por: Morita-Tanaka, Satomi, et al.
Publicado: (2023)

Oncogene alterations in non-small cell lung cancer—have we MET a new target?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Non-small cell lung cancer with MET exon 14 skipping alteration responding to immunotherapy: a case report
por: Chen, Zhuxing, et al.
Publicado: (2021)

Has programmed cell death ligand-1 MET an accomplice in non-small cell lung cancer?—a narrative review
por: Dempke, Wolfram C. M., et al.
Publicado: (2021)

Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial
por: Kim, Seung Tae, et al.
Publicado: (2019)

Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam
por: Ren, Song, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer
por: Ivanina Foureau, Anna V., et al.
Publicado: (2022)

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
por: De Mello, Ramon Andrade, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0lt4gserv4o2fpm25osafmf3e7